Impact News +++ Gerresheimer mit testiertem Nettoverlust 2025 - Ausblick 2026 gesenkt (Dow Jones) +++ GERRESHEIMER Aktie +5,64%

THERAVANCE BIOPHARMA Aktie

>THERAVANCE BIO Aktienkurs

14.8 EUR (TradegateBSX)

Ask: 15 EUR / 319 Stück

Bid: 14.6 EUR / 329 Stück

Tagesumsatz: 0 Stück

Realtime Kurs von 7:30 bis 22 Uhr!

Aktie über LYNX handeln

Intraday

1 Jahr

>THERAVANCE BIO Performance

1 Woche: +6,9%

1 Monat: +9,6%

3 Monate: +17,5%

6 Monate: -1,9%

1 Jahr: +70,7%

laufendes Jahr: -2,8%

>THERAVANCE BIOPHARMA Aktie

Name:

THERAVANCE BIOPHARMA

Land:

China

Sektor:

Gesundheit

ISIN/ Wkn:

KYG8807B1068 / A1137V

Symbol/ Ticker:

0TB (Frankfurt) / TBPH (NASDAQ)

Kürzel:

FRA:0TB, ETR:0TB, 0TB:GR, NASDAQ:TBPH

Index:

Webseite:

https://www.theravance.co..

Profil:

Theravance Biopharma is a biopharmaceutical company focused on discovering, developing, and commercializing small-molecule medicines targeting respiratory disease, inflammatory and immunology conditions, and rare disorders. The company's flagship pro..
>Volltext..

Marktkapitalisierung:

798.38 Mio. EUR

Unternehmenswert:

520.56 Mio. EUR

Umsatz:

96.43 Mio. EUR

EBITDA:

5.08 Mio. EUR

Nettogewinn:

100.62 Mio. EUR

Gewinn je Aktie:

1.99 EUR

Schulden:

64.39 Mio. EUR

Liquide Mittel:

253.08 Mio. EUR

Operativer Cashflow:

236.1 Mio. EUR

Bargeldquote:

12.42

Umsatzwachstum:

57.49%

Gewinnwachstum:

Dividende je Aktie:

Dividendenrendite:

Dividendenschätzung:

Insiderhandel:

1 Insider verkaufte innerhalb der letzten 30 Tage Aktien im Wert von 191.560 Euro.

Suchwörter:

THERAVANCE BIOPHARMA, THERAVANCE BIO

Letzte Datenerhebung:

29.06.26

>Kennzahlen

Aktien/ Unternehmen:

Aktien: 51.55 Mio. St.

Frei handelbar: 93.54%

Leerverk. Aktien: 9.27%

Rückkaufquote: 0.88%

Mitarbeiter: 90

Umsatz/Mitarb.: 1.05 Mio. EUR

Analysten:

Analystenrating: Buy

Kursziel: 6.05%

Bewertung:

KGV: 7.76

KGV lG: 7.15

KUV: 7.59

KBV: 3.03

PEG-Ratio: -

EV/EBITDA: 102.4

Rentabilität:

Bruttomarge: 94.81%

Gewinnmarge: 104.34%

Operative Marge: 0.08%

Managementeffizenz:

Gesamtkaprendite: 28.08%

Eigenkaprendite: 50.17%

>Peer Group

Gesundheit, Lungenerkrankungen & -behandlung/ Asthma, Magen-Darm-Erkrankungen & -behandlung

>THERAVANCE BIO Chart & Kurs - NASDAQ

>THERAVANCE BIO News

29.06.26 - 12:33	Zymeworks to pay $17/share for Theravance Biopharma in $929M deal (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

29.06.26 - 12:03	THERAVANCE BIOPHARMA ENTERS INTO DEFINITIVE AGREEMENT TO BE ACQUIRED BY ZYMEWORKS FOR $17.00 PER SHARE IN CASH PLUS A CONTINGENT VALUE RIGHT (PR Newswire)
	Theravance Biopharma shareholders to receive $17.00 per share in cash, representing an equity value of approximately $929 million Theravance Biopharma shareholders to receive a contingent value right (CVR) entitling them to 80% of net proceeds from any future license, divestiture or other......

29.06.26 - 12:03

Zymeworks to Acquire Theravance Biopharma, Inc. (GlobeNewswire EN)

VANCOUVER, British Columbia, June 29, 2026 (GLOBE NEWSWIRE) -- Zymeworks Inc. (Nasdaq: ZYME) (the “Company”), a biotechnology company managing a portfolio of licensed healthcare assets and developing a diverse pipeline of novel, multifunctional biotherapeutics, today announced it has entered into a definitive agreement to acquire Theravance Biopharma, Inc. (NASDAQ: TBPH); a biopharmaceutical company focused on delivering Medicines that Make a Difference® in people's lives. This proposed acquisition adds YUPELRI®, the first and only nebulized, once-daily, long-acting muscarinic antagonist (LAMA) for the maintenance treatment of chronic obstructive pulmonary disease (COPD), to Zymeworks' partnered portfolio, furthering the Company's commitment to improving outcomes for patients with serious diseases....

29.06.26 - 11:24	Zymeworks Said to Near $929 Million Deal for Theravance (Bloomberg)
	Zymeworks Inc., a Vancouver-based biotechnology company, is in advanced talks to acquire Theravance Biopharma Inc. for $929 million, according to people familiar with the matter....

18.06.26 - 03:01	Insiderhandel: SVP, COMM & MEDICAL AFFAIRS verkauft Aktien von Theravance Biopharma im Wert von 218167 USD (Insiderkauf)
	Farnum, Rhonda - Vorstand - Tag der Transaktion: 2026-06-15...

13.05.26 - 16:45	Are Options Traders Betting on a Big Move in Theravance Biopharma Stock? (Zacks)
	Investors need to pay close attention to TBPH stock based on the movements in the options market lately....

07.05.26 - 14:33	Theravance Biopharma, Inc. Reports First Quarter 2026 Financial Results and Provides Corporate Update (PR Newswire)
	YUPELRI® Collaboration Revenue increased 15% year-over-year1, from $15.4 million to $17.7 million, driven by continued Net Sales growth and improved operating leverage All Hatch-Waxman litigation relating to YUPELRI® has been resolved following settlement with Mankind Pharma in March......

01.05.26 - 04:42	INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Theravance Biopharma, Inc. - TBPH (PR Newswire)
	NEW YORK, April 30, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Theravance Biopharma, Inc. ("Theravance" or the "Company") (NASDAQ: TBPH). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The......

06.04.26 - 19:00	Zacks Industry Outlook Highlights Indivior Pharmaceuticals, Catalyst Pharmaceuticals, Theravance Biopharma, Relmada Therapeutics and Avalo Therapeutics (Zacks)
	Small drug stocks like Indivior gain traction as biotech recovery strengthens, fueled by innovation, M&A activity, and promising pipeline developments....

20.03.26 - 18:45	All You Need to Know About Theravance Bio (TBPH) Rating Upgrade to Strong Buy (Zacks)
	Theravance Bio (TBPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy)....

20.03.26 - 16:30	Here′s Why Theravance Biopharma (TBPH) is a Strong Growth Stock (Zacks)
	Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores....

19.03.26 - 20:03	Theravance Biopharma reports Q4 results (SeekingAlpha)
	Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

19.03.26 - 13:33	Theravance Biopharma, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update (PR Newswire)
	Organizational restructuring and cost reduction plan following results of the Phase 3 CYPRESS study of ampreloxetine are underway; expected to generate $60 - $70 million of annualized cash flow starting in Q3 2026 Strategic Review Committee accelerating evaluation of opportunities to......

19.03.26 - 04:01	Insiderhandel: SVP, COMM & MEDICAL AFFAIRS verkauft Aktien von Theravance Biopharma im Wert von 433637 USD (Insiderkauf)
	Farnum, Rhonda - Vorstand - Tag der Transaktion: 2026-03-16...

04.03.26 - 18:15	TBPH Stock Plunges 26% on Failure of Late-Stage MSA Study (Zacks)
	Theravance Biopharma shares plummet 26% after its phase III CYPRESS study of ampreloxetine missed key endpoints, prompting the company to halt the program....

03.03.26 - 16:36	Theravance Biopharma: Aktie bricht nach gescheiterter Studie um 29 % ein (Investing.com DE)
	Um den gesamten Artikel unter de.investing.com zu lesen, klicken Sie bitte auf die Überschrift...

03.03.26 - 15:31	XFRA: 0TB: Wiederaufnahme/Resumption (XETRA)
	FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE. THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN THERAVANCE BIOPHARMA 0TB KYG8807B1068 AB/FROM ONWARDS 03.03.2026 15:35 CET...

03.03.26 - 15:12	XFRA: 0TB: Aussetzung/Suspension (XETRA)
	DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT: THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL THERAVANCE BIOPHARMA 0TB KYG8807B1068 BAW/UFN...

03.03.26 - 14:39	XFRA: INSTRUMENT_SUSPENSION - KYG8807B1068 (XETRA)
	Instrument ID [7544] (0TB - KYG8807B1068) suspended...

03.03.26 - 14:33	Theravance Biopharma Reports Phase 3 CYPRESS Study Did Not Meet Primary Endpoint; Board Accelerates Strategic Review and Announces Cost Reduction Actions (PR Newswire)
	Phase 3 CYPRESS study did not meet the primary endpoint, the OHSA Composite Score, a patient reported outcome (PRO) Cash of $326.5 million at Q4 2025 (no debt); approximately $400 million expected at end of Q1 2026 including receipt of 2025 milestones; Theravance highly confident in......

>weitere News anzeigen...

>Impressum >Über uns >Datenschutz >Financial Data & Solutions

>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!

Zitat des Tages: Wer zuviel lernen will, der lernt nichts. - Sprichwort Deutschland

Partner: >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook |

Börsentreff auf X |

Börsentreff auf Instagram